Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | FAAH | O00519 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22418877 | 0.90 | SIGMAR1 (0.55) | SIGMAR1FAAHALDH1A1KDM1AKDM4E | |
| SCHEMBL1704512 | 0.85 | ALDH1A1 (0.66) | FAAHALDH1A1POLBLMNAHTT | |
| SCHEMBL4192541 | 0.85 | KMT2A (0.56) | FAAHALDH1A1KDM4ELMNAHTT | |
| SCHEMBL20353635 | 0.85 | FAAH (0.60) | FAAHKDM1A | |
| SCHEMBL24200046 | 0.84 | NPSR1 (0.58) | ALDH1A1KDM4EPKMHRH3LMNA | |
| SCHEMBL29132192 | 0.84 | FNTA (0.52) | ALDH1A1LMNAHTT | |
| SCHEMBL29132085 | 0.84 | SIGMAR1 (0.59) | SIGMAR1FAAHALDH1A1KDM4ELMNA | |
| SCHEMBL4188535 | 0.83 | FAAH (0.54) | FAAHALDH1A1HRH3CYP2D6 | |
| SCHEMBL4595454 | 0.83 | KMT2A (0.57) | FAAHALDH1A1KDM4ELMNATSHR | |
| SCHEMBL25263528 | 0.83 | MMP9 (0.50) | SIGMAR1ALDH1A1KDM1ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| EP-3939954-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-01-19 | — | — | EP | disclosed |
| CN-113518771-A | Method for introducing deuterated lower alkyl into amine part of compound containing secondary amine | 大塚制药株式会社 | 2021-10-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | MGMT, FANCD2, ADAR | SIGMAR1 2839/4885FAAH 533/4885ALDH1A1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.